Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8302826 | PMC |
| http://dx.doi.org/10.1016/j.ijsu.2021.106031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Characteristics, Radiological, and Outcomes of Mucormycosis: A 14-Year Retrospective Study From Southern China.
Mycoses
September 2025
Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Background: Mucormycosis is a rare, rapidly progressive fungal infection with a high mortality rate. However, clinical data of mucormycosis patients, especially those related to adverse outcomes in China, remain limited.
Objective: To enhance understanding of the clinical characteristics of different infection site mucormycosis and identify the factors associated with adverse outcomes.
Pathologically Confirmed Dual Coronavirus Disease 2019-Associated Tracheobronchial Aspergillosis and Pulmonary Mucormycosis in a Non-Endemic Region: A Case Report.
J Clin Med
August 2025
Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea.
Coronavirus disease 2019 (COVID-19) has led to the expansion of the spectrum of invasive fungal infections beyond traditional immunocompromised populations. Although COVID-19-associated pulmonary aspergillosis is increasingly being recognised, COVID-19-associated mucormycosis remains rare, particularly in non-endemic regions. Concurrent COVID-19-associated invasive tracheobronchial aspergillosis and pulmonary mucormycosis with histopathological confirmation is exceedingly uncommon and poses significant diagnostic and therapeutic challenges.
View Article and Find Full Text PDFSuccessful Treatment of Mucormycosis and Azole-Resistant Coinfection in a Diabetic Patient: A Case Report.
Infect Drug Resist
July 2025
Department of Respiratory and Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu, 210008, People's Republic of China.
Objective: To report a case of coinfection with mucormycosis and azole-resistant in a patient with poorly controlled type 2 diabetes, highlighting successfully treated with high-dose posaconazole combined with liposomal amphotericin B and lobectomy.
Methods: A 52-year-old man who presented to our hospital with a 1-month history of fever accompanied by productive cough and sputum. He had type 2 diabetes with poor control of glucose level.
Invasive Mucormycosis in a Chronic Lymphocytic Leukemia Patient on Zanubrutinib: A Case Report.
Infect Drug Resist
July 2025
Jiangxi Key Laboratory of Oncology (2024SSY06041), JXHC Key Laboratory of Tumour Metastasis, NHC Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma, Jiangxi Cancer Hospital & Institute, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, 330
Background: Invasive mucormycosis is a severe fungal infection that predominantly affects immunocompromised and diabetic patients. This case study highlights the importance of early diagnosis and pathogen-specific antifungal therapy in managing invasive mucormycosis among high-risk patients.
Case Description: A 47-year-old male with chronic lymphocytic leukemia (Rai stage IV) on zanubrutinib and with uncontrolled diabetes was admitted to Jiangxi Cancer Hospital on November 7, 2021.
Mucormycosis in patients infected with the delta strain of COVID-19 virus, effective of some factors in the prevalence and patient prognosis in Shahid Beheshti Hospital, Kashan, central Iran.
Caspian J Intern Med
March 2025
Department of Radiology, Kashan University of Medical Sciences, Kashan, Iran.
Background: Opportunistic infections such as mucormycosis, are spread in COVID-19 patients due to the use of corticosteroids therapy. This study aimed to determine the prevalence of mucormycosis in patients infected with the delta strain of the COVID-19 virus and evaluated some effective factors in the prevalence and patient prognosis.
Methods: This study was performed on 44 COVID patients with co-infection to mucormycosis who were admitted to Shahid Beheshti Hospital, Kashan in 2022.